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177Lu-labeled nanoparticles conjugated to biomolecules have been proposed as a new class of theranostic radiopharmaceuticals.
The aim of this research was to synthesize 177Lu-dendrimer(PAMAM-G4)-folate-bombesin with gold nanoparticles (AuNPs) in
the dendritic cavity and to evaluate the radiopharmaceutical potential for targeted radiotherapy and the simultaneous detection of
folate receptors (FRs) and gastrin-releasing peptide receptors (GRPRs) overexpressed in breast cancer cells. p-SCN-Benzyl-DOTA
was conjugated in aqueous-basic medium to the dendrimer. The carboxylate groups of Lys1Lys3(DOTA)-bombesin and folic acid
were activatedwithHATUand also conjugated to the dendrimer.The conjugatewasmixedwith 1%HAuCl
4
followed by the addition
of NaBH
4
and purified by ultrafiltration. Elemental analysis (EDS), particle size distribution (DLS), TEM analysis, UV-Vis, and
infrared and fluorescence spectroscopies were performed. The conjugate was radiolabeled using 177LuCl
3
or 68GaCl
3
and analyzed
by radio-HPLC. Studies confirmed the dendrimer functionalization with high radiochemical purity (>95%). Fluorescence results
demonstrated that the presence of AuNPs in the dendritic cavity confers useful photophysical properties to the radiopharmaceutical
for optical imaging. Preliminary binding studies in T47D breast cancer cells showed a specific cell uptake (41.15 ± 2.72%). 177Lu-
dendrimer(AuNP)-folate-bombesin may be useful as an optical and nuclear imaging agent for breast tumors overexpressing GRPR
and FRs, as well as for targeted radiotherapy.
1. Introduction
Dendrimers are hyperbranched polymeric structures varying
in their initiator core, repeating units, terminal functionality,
charge, and solubility profile. A drug can be entrapped
either within the internal cavities or conjugated to periph-
eral functional groups of the dendrimer. Polyamidoamine
(PAMAM) dendrimers are spherical macromolecules com-
posed of repeating polyamidoamine units which are known
to have low biological toxicity, good biocompatibility, and in
vivo stability [1, 2].
Gold nanoparticles (AuNPs) conjugated to peptides or
biomolecules with target-specific recognition produce stable
multimeric systems with target-specific molecular recogni-
tion. Plasmonic AuNPs can be fluorescent when they are
prepared by thermal reduction procedures or when they are
designed to absorb in the near infrared region; therefore,
AuNPs can also function as optical imaging agents [3, 4].
Over the last two decades, several experimental evidences
have suggested that the gastrin-releasing peptide (GRP)
and other bombesin-like peptides act as growth factors in
many types of cancer [5]. Overexpression of gastrin-releasing
peptide receptors (GRPR) is present in 96% of breast cancer
tissues [6]. Different bombesin analogues with high affinity
for GRPR have been evaluated in preclinical studies for
receptor-specific imaging and therapy [5]. Clinical studies
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in women using radio-bombesin derivatives have shown
successful radionuclide imaging of breast tumors [7–10]. In
particular, the GRPR is highly expressed in T47D human
breast cells, and that is the reason why these cells have been
used as tumor models to evaluate new bombesin probes
[6, 11–13].
Folate receptor-𝛼 (FR𝛼) is a membrane-bound protein
with high affinity for binding and transporting folate into
cells. Folate is a basic component of cell metabolism and
DNA synthesis and repair. Cancer cells, which rapidly divide,
have an increased requirement for folate to maintain DNA
synthesis, an observation supported by the widespread use of
antifolates in cancer chemotherapy [14, 15].
The overexpression of FR𝛼 protein has been confirmed
in all clinical breast cancer subtypes, comprised of estro-
gen receptor-positive (ER+), progesterone receptor-positive
(PR+), human epidermal growth factor receptor-positive
(HER2+), and triple negative (ER−, HER2−, and PR−)
tumors [16–18]. Recent polymerase chain reaction studies
confirmed that FR𝛼 is highly expressed in T47D cells [19].
An in vivo theranostic approach combines the poten-
tial of both diagnosis and therapy in the same targeting
molecule by labeling with either a diagnostic or a suitable
therapeutic radionuclide. Theranostic radiotracers provide
patients with targeted and personalized treatment options,
thereby improving the current clinical treatment options
at the same time. In the field of nuclear medicine, 177Lu-
labeled AuNPs conjugated to different peptides have been
proposed as a new class of theranostic radiopharmaceuticals
[20]. These multifunctional systems contain the chelator
DOTA, able to complex both 68Ga and 177Lu, which could
be useful for the identification of malignant tumors, and
monitoring of treatment (SPECT/NIR fluorescence optical
imaging), for targeted radiotherapy (𝛽-particle-energy deliv-
ered per unit of targetedmass), and for photothermal therapy
(localized heating). Therefore, a multifunctional system of
DOTA-dendrimer-AuNP conjugated to bombesin and folate
is expected to improve both the recognition of breast cancer
cells positive to FR and GRPR and its theranostic properties
when labeled with 68Ga and 177Lu.
The aim of this work was to synthesize 177Lu-DOTA-den-
drimer-folate-bombesin with gold nanoparticles in the den-
dritic cavity (177Lu-DenAuNP-folate-bombesin) and to eval-
uate the radiopharmaceutical potential for targeted radio-
therapy and the simultaneous detection of FRs and GRPRs
overexpressed in T47D breast cancer cells. In order to probe
the theranostic potential, the labeling of DenAuNP-folate-
bombesin with 68Ga was also accomplished.
2. Materials and Methods
2.1. Materials. G4-PAMAM-(NH
2
)
64
dendrimer (10%wt. in
methanol, density 0.813 g/mL) [dendrimer] and folic acid
were purchased from Sigma-Aldrich Chemical Co. (St.
Louis, Missouri, USA). H
2
N-Lys1Lys3(DOTA)-bombesin (1–
14) peptide [bombesin] with a purity of >90% (HPLC)
was obtained from piChem Laboratory (Graz, Austria). The
bifunctional chelating agent S-2-(4-Isothiocyanatobenzyl)-
1,4,7,10-tetraazacyclododecane tetraacetic acid (p-SCN-Bn-
DOTA) [DOTA] was obtained from Macrocyclics (Dallas,
TX, USA). All other chemicals were also purchased from
Sigma-Aldrich Chemical Co. and used without additional
purification.
2.2. Synthesis and Chemical Characterization
2.2.1. Conjugation of DOTA to the Dendrimer. Fifty micro-
liters of dendrimer (0.3𝜇mol) in methanol was dried under
vacuum and redissolved in 0.5mL of 0.2M sodium bicarbon-
ate buffer, pH 9.5.The above solutionwas then incubatedwith
DOTA (5.38 𝜇mol; 3.7mg in 0.5mL of 0.2M sodium bicar-
bonate buffer, pH 9.5) at 37∘C during 1 h (DOTA/dendrimer
molar ratio of 18/1). The final reaction mixture was washed
three times with type I water by ultrafiltration to remove
bicarbonate buffer (Ultrafree-PFL Filters, MWCO 10,000,
polysulfone membrane, Millipore) and finally lyophilized.
2.2.2. Activation of Carboxylate Groups of Folic Acid and Bomb-
esin. Folic acid (2.27 𝜇mol; 1mg) and bombesin (0.55 𝜇mol,
1.1mg) were dissolved in 200𝜇L of dimethylformamide
(DMF) and were added to a mixture containing 100 𝜇L of
0.2M diisopropylethylamine (DIPEA, to provide a basic
medium) (114.83 𝜇mol; 14.84mg in 300𝜇L of DMF) and
100 𝜇L of the carboxylate activating agent HATU (O-(7-
azabenzotriazol-1-yl)-N,N,N󸀠,N󸀠-tetramethyluronium-hexa-
fluoro phosphate), (15.78 𝜇mol, 6mg in 100 𝜇L of DMF).
The reaction mixture was incubated for 15min at room
temperature (20∘C).
2.2.3. Conjugation of Bombesin and Folic Acid to the Amine
Groups on the Dendrimer. The lyophilizedDOTA-dendrimer
(0.35 𝜇mol) was dissolved in 100𝜇L of DMF and added to the
above activated carboxylate folate-bombesin solution. The
mixture was incubated during 1.5 h at room temperature.The
obtained precipitate was washed with DMF and dried under
vacuum.Themolar ratio of dendrimer to folate was 1 : 6.5 and
1 : 1.5 for dendrimer to bombesin.
2.2.4. Synthesis ofDenAuNP-Folate-Bombesin. To an aqueous
solution of Den-folate-bombesin (1.4mg/mL, 0.1 𝜇mol) 1%
HAuCl
4
(170 𝜇L, 5 𝜇mol) was added under vigorous stir-
ring. After 60min, 0.56mL of an ice-cold NaBH
4
solution
(1mg/mL, 15𝜇mol) was added to the gold dendrimermixture
under stirring. Within a few seconds, the reaction mixture
turned deep-red and the stirring process was continued for
2 h to complete the reaction.Thefinal product was purified by
ultrafiltration (Ultrafree-PFLFilters,MWCO10,000, polysul-
fone membrane, Millipore) and finally lyophilized to obtain
DenAuNP-folate-bombesin. For comparative purposes the
DenAuNP compound was also prepared under the same
procedure.
Journal of Nanomaterials 3
2.3. Chemical Characterization
2.3.1. IR Spectroscopy. IR spectra of dendrimer, folate,
Lys1Lys3(DOTA)bombesin (1–14), p-SCN-Bn-DOTA, Den-
folate-bombesin, and Den(AuNP)-folate-bombesin, in solid
state, were obtained on a Perkin-Elmer System spectrometer
(Spectrum 400) (Waltham, MA, USA) with an attenuated
total reflection platform (DiamondGLADIATOR, Pike Tech-
nologies; Madison, WI, USA), from 500 to 4000 cm−1.
2.3.2. Transmission Electron Microscopy (TEM). TEM was
performed using a JEOL-EMDSC-U10A instrument (JEOL,
Japan) operating at 200 kV. The samples of each compound
(DenAuNP or DenAuNP-folate-bombesin) were analyzed
stained and unstained. The samples were dropped onto a
carbon-coated copper grid and allowed to evaporate under
vacuum before measurements. Some samples of both com-
pounds were then stained with an aqueous solution of
phosphotungstic acid (2%w/w) and dried.
2.3.3. Dynamic Light Scattering (DLS) and Zeta Potential
Measurement. The DLS and Zeta potential measurement
were performed using a Nanotrac Wave (Model MN401,
Microtract, FL, USA). The temperature of the cell housing
was set to 22.6∘C.The data was acquired fromDenAuNP and
DenAuNP-folate-bombesin samples diluted in MilliQ water
(𝑛 = 3). The hydrodynamic diameter and Zeta potential were
obtained for each sample.
2.3.4. Scanning Electron Microscopy (SEM) and X-Ray Anal-
ysis. The multifunctional DenAuNP-folate-bombesin was
visualized by scanning electron microscopy (SEM). The
sample was mounted on an aluminum stub using double-
sided tape.The coated samplewas examinedusing an electron
acceleration voltage of 20–25 keV (JEOL JSM-5900 Low
Vacuum, USA). The X-ray analysis was obtained from a
selected area of the sample using the above system.
2.3.5. Fluorescence Spectroscopy. Emission fluorescence spec-
tra ofDenAuNP-folate-bombesin, Den-folate-bombesin, and
dendrimer samples in solid state (powder) at 291 K were
recorded on a Perkin-Elmer LS-55 low-resolution lumines-
cence spectrometer, from 200 to 900 nm. The best results
were obtained using an excitation wavelength (𝜆exc) of
222 nm, emission filter of 290 nm, and excitation and emis-
sion slits of 5 nm for the three samples.
2.4. Preparation of 68Ga-/177Lu-DenAuNP-Folate-Bombesin.
Radiolabeling with 177Lu was carried out by adding 177LuCl
3
solution (20𝜇L, 1.1 GBq, 3 TBq/mg, ITG, Germany) to the
DenAuNP orDenAuNP-folate-bombesin conjugate (50𝜇g in
a solution of 200𝜇L of 0.25M acetate buffer, pH 5.5) and
incubating it at 37.5∘C for 20min. For 68Ga labeling, 68GaCl
3
was obtained from a 68Ge/68Ga-Generator (ITG, Germany)
eluted with 0.5M HCl to which (1mL) 50𝜇g of DenAuNP-
folate-bombesin conjugate was added in a solution of 1mL of
0.5M acetate buffer, pH 4.0, incubating it at 90∘C for 10min.
The radiochemical purity was determined using a radio-
HPLC size-exclusion system (ProteinPak 300SW, Waters,
1mL/min, NaHCO
3
0.2M, pH 9.5). Chromatographic pro-
files were obtained using two different detectors, the UV-Vis
detector and a radiometric detector. The sample first passed
through the UV-Vis detector (photodiode array) and after
0.5min (0.5mL, 1mL/min), it passed through the radioactiv-
ity detector. The retention times in this system were 𝑡
𝑅
= 7.80
and 8.31min in the chromatogram and radiochromatogram,
respectively. Correspondence in retention times of the peaks
of interest in the chromatogram is commonly accepted as a
proof of the chemical identity of the radiopharmaceutical.
For comparative studies, 177Lu-folate-bombesin was also
prepared as previously reported by Aranda-Lara et al. [21].
2.5. In Vitro Studies
2.5.1. Stability in Human Serum. To determine the stability
of 177Lu-DenAuNP-folate-bombesin in serum, 200𝜇L of
radiotracer was diluted at a ratio of 1 : 10 with fresh human
serum and incubated at 37∘C. Radiochemical stability was
determined with a 100 𝜇L sample taken at 24 h for radio-
HPLC size-exclusion analysis (ProteinPak 300SW, Waters,
1mL/min, PBS).
2.5.2. Cell Culture. A T47D human breast cancer cell line
(obtained fromATCC,USA)was grown at 37∘Cwith 5%CO
2
and 85% humidity in folate-free RPMI-1640 culture medium
supplemented with 10% fetal bovine serum and 1% antibiotics
(streptomycin and penicillin).
2.5.3. Cell Uptake Studies. T47D cancer cells suspended
in fresh medium were diluted to 4 × 106 cells/tube with
PBS at pH 7.4 or pH 5.3 (mimicking the acidic condi-
tions within tumors) and incubated with 20 𝜇L (0.9MBq)
of 177Lu-DenAuNP-folate-bombesin, 177Lu-DenAuNP, or
177Lu-folate-bombesin in triplicate at 37∘C for 1 h. The test
tubes were centrifuged at 2500 rpm for 5min and washed
with phosphate-buffered saline. Radioactivity in the cell
pellet represents both membrane-bound and internalized
radiopharmaceutical and was measured in a crystal scintilla-
tionwell-type detector (Auto In-v-tron 4010, NML, Inc.).The
membrane-bound activity was removed with 1mL of 0.2M
acetic acid/0.5M NaCl solution added to the cell pellet. The
test tubes were centrifuged and the pellet activity, which was
considered as internalization,wasmeasured. Blocking studies
were carried out in parallel. The cells were preincubated with
100 𝜇L of folic acid in 0.01M NaOH (0.5mM) or 100 𝜇L of
Lys3-bombesin (0.5mM) for 5min before addition of the
radiopharmaceutical.
2.6. In Vivo Uptake
2.6.1. Animal Model. In vivo studies in mice were carried
out according to the rules and regulations of the Official
Mexican Norm 062-ZOO-1999. Athymic mice, 6-7 weeks old
and 18–20 g weight, were kept in sterile cages with sterile
wood-shaving beds, constant temperature, humidity, noise,
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Figure 1: Overall scheme of 177Lu-DenAuNP-folate-bombesin.
and 12:12 light periods. Athymic mice were maintained on a
folate-free diet for 3 weeks before imaging studies.
2.6.2. Tumor Induction. Athymic female mice (6-7 weeks
old, 𝑛 = 4) were inoculated subcutaneously in the upper
back with 2 × 106 T47D cancer cells suspended in 0.1mL of
phosphate-buffered saline. Injection sites were observed at
regular intervals for tumor formation and progression.
2.6.3. 177Lu-DenAuNP-Folate-Bombesin Imaging. To verify
the in vivo radionanoconjugate retention in tumors, optical
images were acquired at 1 h and 96 h after 177Lu-DenAuNP-
folate-bombesin intratumoral administration (37MBq) in
T47D tumor-bearing mice using a preclinical optical/X-ray
imaging system (in vivo X-Treme, Bruker BioSpin Corp.,
USA).Mice under 2% isoflurane anesthesiawere placed in the
prone position and whole imaging was performed. Counts in
the tumor were quantified at 1 and 48 h after injections.
3. Results and Discussion
3.1. Synthesis and Chemical Characterization
Synthesis. The overall scheme of the theranostic radio-
pharmaceutical 177Lu-DenAuNP-folate-bombesin is shown
in Figure 1. The DenAuNP-folate-bombesin conjugate was
obtained as a black solid with an overall yield of 72%.
IR Spectroscopy. The IR spectra of the dendrimer, bombesin,
DOTA, folic acid, DenAuNP, Den-folate-bombesin, and
Journal of Nanomaterials 5
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Figure 2: IR-spectrum of (a) dendrimer, (b) bombesin, (c) DOTA,
(d) folic acid, (e) DenAuNPs, (f) Den-folate-bombesin, and (g)
DenAuNP-folate-bombesin.
DenAuNP-folate-bombesin are presented in Figure 2.The IR-
spectrum of Den-folate-bombesin reveals some characteris-
tic bands from the dendrimer, bombesin, DOTA, and folic
acid, which change in intensity and positions or disappear
because of the conjugation to the dendrimer. In agreement
with the IR spectra of bombesin and folic acid described
by Aranda-Lara et al. [22], the strong bands in the 1646–
1533 cm−1 region from the bombesin spectrum (Figure 2(b))
and 1687 cm−1 and 1637 cm−1 from folic acid (Figure 2(d))
which correspond to amide I and amide II vibrations disap-
peared or decreased in intensity in the Den-folate-bombesin.
A change of symmetry occurs in this supramolecule and
bands associated with the formation of new secondary
amides increase the absorbance of bands at 839 and 555 cm−1,
which correspond to a symmetrical C-N-C stretching vibra-
tion and to the bendingmotion ofO=C-N group, respectively
[23]. In the dendrimer spectrum (Figure 2(a)), three weak
well-defined bands at 1152, 1130, and 1032 cm−1 are observed.
After conjugation (Den-folate-bombesin), the spectrum (Fig-
ure 2(f)) revealed two red-shifted bands (7 cm−1 and 5 cm−1)
at 1171 and 1123 cm−1, from bombesin: one band at 1033 cm−1
from the dendrimer and two semishoulders at 1100 and
1065 cm−1, from DOTA (Figure 2(c)) and folic acid (Fig-
ure 2(d)). In the DenAuNP spectrum, two bands at 1146 and
1031 cm−1, from the dendrimer, are observed and the pattern
of the spectrum changed (Figure 2(e)), which indicates the
encapsulation of the AuNPs with effect on the molecular
symmetry of the dendrimer. Structured new regions between
3900 and 3600 cm−1 (centered at 3747 cm−1), and between
2250 and 1700 cm−1 (centered at 2011 cm−1), are observed
and seem to correspond to weak hydrogen bonding between
the dendrimer amides as the result of the entrapped AuNPs.
The change in the spectrum of Den-folate-bombesin after
the encapsulation of AuNPs (DenAuNP-folate-bombesin)
(Figure 2(g)) suggests a newmolecule with particular physic-
ochemical properties. The weak bands between 1200 and
900 cm−1 observed in Den-folate-bombesin spectrum are
the most strong in that of DenAuNP-folate-bombesin. The
bands at 1157 and 1029 cm−1 are from the dendrimer and
those at 1102 and 1051 cm−1 (14 cm−1 red-shifted) are from
the molecules conjugated to the dendrimer (Figure 2(g)).
Their increase in absorbance seems to be the result of the
encapsulation of AuNPs in the dendritic cavity. The bands
observed between 1200 and 1000 cm−1 correspond to C-
N stretching vibrations from primary amides, secondary
amides, and tertiary aliphatic amines [23]. In particular, CN
vibrations from tertiary aliphatic amines are located between
1040 and 1020 cm−1 [23].
In the DenAuNP-folate-bombesin spectrum, two new
structured regions with two maximum bands at 3753 and
2015 cm−1 slightly blue shifted with respect to those of
the DenAuNP are observed, which demonstrates that the
entrappedAuNPs favoredweak interactions in the dendrimer
cavity.
IR suggests that AuNPs are entrapped in the dendritic
cavity inDen-AuNPs and inDen-AuNP-folate-bombesin, but
in the former the bands of the dendrimer are not strong. In
contrast, the conjugation of bombesin, folic acid, and DOTA
to the dendrimer induces a particular structural arrangement
which allows the encapsulation of the AuNPs in the dendritic
cavity and affords a larger stability and an adequate symmetry
to the supramolecule, which is revealed in the particular
feature of the spectrum and the very strong bands associated
with the -C-N- groups.
Transmission ElectronMicroscopy. TEM images ofDenAuNP-
folate-bombesin (Figure 3(a)) show single units of the com-
pounds as grayish round objectswith amean diameter of 5.6±
0.4 nm,which is slightly greater than that ofDenAuNP (4.53±
1.33 nm, Figure 3(b)) because of the conjugation with folate
and bombesin. The increase in the hydrodynamic diameter
of DenAuNP-folate-bombesin by the conjugation effect was
observed by TEM as a halo around the compound due to
the poor interaction of the electron beam with the folate and
bombesin molecules (low electron density), in contrast to
the strong scattering of the electron beam when it interacted
with the metallic nanoparticles [24]. Each compound shows
small black dots that correspond to the gold nanoparticles
with approximate average diameter of 2.5±0.4 nm.According
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Figure 3: TEM image and size distribution (DLS) of (a) DenAuNP-folate-bombesin and (b) DenAuNP.
to the previous studies, the black dots indicate that gold
nanoparticles are in the dendritic cavity [25].
Particle Size and Zeta Potential. The hydrodynamic diameter
of DenAuNPs and DenAuNP-folate-bombesin by DLS was
5.00 ± 1.47 nm and 18.60 ± 8.00 nm, respectively (Figure 3).
The𝑍 potential of the DenAuNP-folate-bombesin was 86.3±
3.8mV, versus 28.6 ± 2.7mV for the DenAuNPs, indicating
that the folate and bombesin conjugation confers a high
colloidal stability to the multifunctional system.
Scanning Electron Microscopy. The SEM image (Figure 4(a))
showed that the DenAuNP-folate-bombesin conjugate has
a granular and homogeneous structure. The qualitative ele-
mental content determined by X-ray analysis for DenAuNP-
folate-bombesin (Figure 4(b)) shows the presence of Au and
S as well as C, N, and O.
UV-Vis. The Den-folate-bombesin spectrum showed bands
associated with DOTA (shoulder at 258 nm), bombesin
(278 nm), and folate (284 nm and a shoulder at 340 nm) (Fig-
ure 5(a)), whichweremasked in the presence of the entrapped
AuNPs (Figure 5(b)). The DenAuNP-folate-bombesin spec-
trum exhibited a surface plasmon resonance as a shoulder
at approximately 510 nm (Figure 5(b)). The plasmon band
is associated with the average contribution of the entire
AuNP population, but only the AuNPs with diameters larger
than 2.5 nm significantly contribute to the plasmon band
absorption at 510 nm [25, 26]. Several groups have reported
the presence of intradendrimer encapsulated nanoparticles,
in which the nanoparticle resides within the interior void
space of the dendrimer, as well as interdendrimer-stabilized
nanoparticles, in which the nanoparticle surface is stabi-
lized by multiple dendrimers through their terminal amine
groups. Intradendrimer nanoparticles are usually smaller
than 4.5 nm; in contrast, interdendrimer particles are always
larger than 5 nm [26]. In this research, the encapsulation of
2.1–2.9 nm diameter nanoparticles within single dendrimers
observed in TEM images suggests that formation of gold
interdendrimer particles did not occur, possibly due to the
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Figure 6: Emission fluorescence spectra in powder at 291 K of (A)
DenAuNP-folate-bombesin, (B) Den-folate-bombesin (𝜆emi = 311,
347, 383, 421, 444, 485, and 529 nm), and dendrimer (𝜆emi = 308, 345,
384, 419, 445, 484, and 520 nm).The three spectra were measured at
𝜆exc = 222 nm, slitexc = 5.0 nm, slitemi = 5.0 nm, and filter = 290 nm.
steric effect of bombesin, folate, andDOTA on the dendrimer
surface. The band at 290 nm is reproducibly observed during
the syntheses of AuNPs through the use of dendrimers as
templates [27]. This band and the plasmon band absorption
are also observed in the DenAuNPs spectrum (Figure 5(c)).
The surface plasmon resonance observed at 510 nm opens
the possibility for further studies related to plasmonic pho-
tothermal therapy [28]. Several trials have demonstrated
a significant improvement in the clinical outcome when
radiotherapy was conducted under hyperthermic conditions
in patients [29]. Hyperthermia increases the efficacy of
radiotherapy by improving tumor oxygenation and interfer-
ing with the DNA repair mechanisms. By exposing 177Lu-
DenAuNP-folate-bombesin to laser irradiation, it could be
possible to heat a localized area in the tumor without any
harmful heating of the surrounding healthy tissues.
Fluorescence Spectroscopy. Figure 6 shows the selected flu-
orescence emission spectra of the dendrimer, Den-folate-
bombesin, and Den-AuNP-folate-bombesin from the lumi-
nescence studies. Two important aspects are observed, the
enhanced luminescence of the DenAuNP-folate-bombesin
(Figure 6(A)) with respect to the dendrimer and Den-
folate-bombesin, and the presence of new peaks at 761 and
843 nm. The high luminescence intensity is caused by the
encapsulated small AuNPs that induce the stabilization of the
molecule and the NIR emissions. This fact pointed to the
presence of NIR-emitting gold nanoclusters (NCs), possibly
in the form of (Au0)
50
-dendrimer-G4. Recent developments
in the NC field have demonstrated that metal NCs are
excellent luminescent materials [3, 30]. The luminescent
properties of the DenAuNP-folate-bombesin conjugate are
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Figure 7: Size-exclusionHPLC chromatogram (220 nm; continuous
line) and HPLC radiochromatogram (dotted line) of the 177Lu-
DenAuNP-folate-bombesin theranostic radiopharmaceutical (flow
rate 1mL/min). 68Ga-DenAuNP-folate-bombesin showed the same
retention time (7.8 ± 0.2min).
relevant because it could be used in animal imaging. Recently,
Wu et al. investigated tumor targeting of NIR-emitting BSA-
stabilized AuNCs, and the NIR fluorescence significantly
improved tissue penetration depth up to fewmillimeters [31].
Radiolabeling. The size-exclusion HPLC chromatogram and
radiochromatogram of the purified multifunctional system
(Figure 7) show that both 68Ga- or 177Lu-DenAuNP-folate-
bombesin were obtained with a radiochemical purity of
97 ± 2%, without postlabeling purification (𝑛 = 20).
After incubation of the 177Lu-DenAuNP-folate-bombesin
radiopharmaceutical in human serum (24 h at 37∘C), the
radio-HPLC chromatogram showed a radiochemical purity
of >90%, which demonstrates its high stability in serum.
3.2. T47D Cancer Cell Studies. Preliminary cell studies
showed an important uptake of 177Lu-DenAuNP-folate-
bombesin in T47D cancer cells, which was significantly (𝑡-
student, 𝑝 < 0.05) inhibited by preincubation with cold
Lys3-bombesin peptide or folic acid alone, indicating that the
multifunctional system has specific recognition for GRPRs
and FRs (Figure 8).The T47D cell uptake of 177Lu-DenAuNP
was 9.84 ± 1.14%, mainly attributed to a passive uptake
mechanism [24], and significantly (𝑡-student, 𝑝 < 0.05)
lower than that of 177Lu-DenAuNP-folate-bombesin (41.15±
2.72%).
At pH 7.4, the preincubation with cold Lys3-bombesin
showed greater blocking effect on the multifunctional system
(62.14% less uptake) compared with that of the cold folic
acid (36.53% less uptake) (Figure 8).This difference in block-
ing effect is consistent with the GRP and folate receptors’
expression levels in T47D breast cancer cells [21, 22], which
suggest that the specific targeting of the 177Lu-DenAuNP-
folate-bombesin in T47D is mainly dominated by the specific
recognition of the bombesin moiety through GRP receptors.
It is important tomention that, at pH=5.3 and in the presence
of cold bombesin or cold folic acid in blocking studies, the
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Figure 8: In vitro uptake of 177Lu-DenAuNP-folate-bombesin in T47D breast cancer cells at 1 h. (A) Unblocked, (B) blocked with folic acid,
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Figure 9: Optical imaging of 177Lu-DenAuNP-folate-bombesin at 1 h and 96 h after intratumoral administration.
observed effect is an increase in the 177Lu-DenAuNP-folate-
bombesin cell uptake (77.6 ± 9.5%) possibly related to the
dendrimer cellular adsorption [32].
The in vitro T47D cell uptake was higher for
177Lu-DenAuNP-folate-bombesin (41.15 ± 2.72%) than
that reported for the 177Lu-folate-bombesin conjugate
(33.27 ± 2.52%) [22]. This effect could be associated with the
multivalent ligand-receptor binding of the 177Lu-DenAuNP-
folate-bombesin, since the peptide-nanoparticle conjugate
provides a surface for simultaneous interactions with the
cell surface, giving rise to multivalent effects (defined as an
affinity enhancement) [24], as well as to the contribution of
dendrimer passive uptake [24]. Nevertheless, further studies
related to cell internalization and affinity must be carried
out.
Preliminary in vivo imaging studies demonstrated that
177Lu-DenAuNP-folate-bombesin remained in the T47D
tumor up to 96 h after intratumoral radiopharmaceutical
administration, since in all mice the tumor intensity in the
optical imaging correlated with the radionuclide decay (e.g.,
at 1 h = 11354 photons/s/mm2; at 96 h = 6830 photons/s/mm2)
with only 9 ± 5% of biological elimination (Figure 9).
Considering that one Becquerel (Bq) of Lu-177 produces
841558 disintegrations until total decay (total disintegra-
tions = ∫𝑡
0
𝐴(𝑡)𝑑𝑡) with a maximum 𝛽−-particle energy of
0.498MeV, it is expected that, with the high 177Lu-DenAuNP-
folate-bombesin retention observed in tumors, the total radi-
ation absorbed dose to themalignant tissue could easily reach
2Gy per MBq [33]. However, further preclinical studies must
10 Journal of Nanomaterials
be carried out in order to evaluate the toxicity, biokinetics,
and dosimetry of this radiopharmaceutical.
An important benefit of receptor-specific radiopharma-
ceuticals is their potential for use in targeted radiotherapy.
Multiple peptides, specific to target receptors that are over-
expressed in breast cancer cells, appended to one nanopar-
ticle and radiolabeled with an imaging and 𝛽− particle-
emitting radionuclide (177Lu), act as a multifunctional sys-
tem that could be useful in identifying malignant tumors
and metastatic sites (by single photon emission computed
tomography imaging, “SPECT”), for targeted radiotherapy
(high 𝛽-particle-energy delivered per unit of targeted mass),
and for thermal therapy (localized heating after laser irra-
diation). However, for therapeutic purposes, NPs should be
administered by intratumoral injection or into a selective
artery to avoid high uptake by organs of the reticuloen-
dothelial system due to the colloidal nature of NPs [33].
Injection into a breast tumor would allow high uptake into a
tumor, possible micrometastases, or individual cancer cells.
Therefore, 177Lu-DenAuNP-folate-bombesin has potential
application in medical diagnosis and therapeutic treatments
due to its unique combination of radioactive, optical, and
thermoablative properties. This study demonstrated that the
nanosystem exhibited chemical and physical properties that
are suitable for plasmonic photothermal therapy and targeted
radiotherapy in the treatment of breast cancer.
4. Conclusions
Elemental analysis and spectroscopy techniques showed that
folic acid, bombesin, and DOTAmolecules were successfully
conjugated to one molecule of the PAMAM dendrimer.
Chromatographic studies showed that the 68Ga- and 177Lu-
DenAuNP-folate-bombesin conjugate were obtained with
high radiochemical purity (>95%). Preliminary binding stud-
ies in T47D breast cancer cells indicated a specific cell uptake
and high retention in T47D-induced tumors in mice.
Luminescence results show that AuNPs in the conjugate
increase the fluorescence intensity, resulting in a multifunc-
tional system that may be useful as an optical and nuclear
imaging agent for breast tumors overexpressing GRPRs and
FRs, as well as for targeted radiotherapy.
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